Navigation Links
Bioheart, Inc., Added to Russell Microcap Index
Date:7/2/2008

SUNRISE, Fla., July 2 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced it has been added to the Russell Microcap Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.

According to the Russell Investment Group, the Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for passive and active investment strategies. The Company will hold its membership until Russell reconstitutes its indexes in June 2009.

"We are pleased with our inclusion in this index, which reflects our continued momentum," said William Kline, Chief Financial Officer, Bioheart, Inc. "We are confident that our inclusion in this index will generate greater interest in our stock among institutional investors."

The Russell Microcap Index measures the performance of the microcap segment of the U.S. equity market. It includes 1,000 of the smallest securities in the small-cap Russell 2000(R) Index based on a combination of their market cap and current index membership as well as the next 1,000 securities below the index.

ABOUT BIOHEART, INC.

Bioheart, Inc. (NASDAQ: BHRT) is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical cell therapy designed to populate regions of scar tissue within a patient's heart with
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. BSP Pharma Inc., Makers of FlexNow(TM) Joint Formula Sign Distribution Deal with Vitamin Shoppe and GNC
7. The PLSG Invests $150,000 in Coventina Healthcare Enterprises, Inc., Its Eighth Company Relocation to Pittsburgh
8. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
9. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
10. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
11. LS9, Inc., the Renewable Petroleum Company(TM), Adds Key Positions to Executive Team and Scientific Advisory Board

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCo...evelopmentAuthority(OPDA)wererecentlyawarded$2mill...ionBoard(CERB)inaprivate/publicpartnershiptoconstr...nLincolnCounty,WA. ,, "Thisinvestmentwillsignif...over70greenjobstoLincolnCounty,"saidBlueMarbleEner...
(Date:11/24/2009)..., DUBLIN,November24/PRNewswire-FirstCall/--Shire...pharmaceuticalcompany,today,announcedthatithassubm...rasealfa,thecompany,senzymereplacementtherapyindev...isthethirdmarketing,applicationforvelaglucerasealf...eUnitedStatesandCanada. , Basedonaglobalsuppl...
(Date:11/24/2009)... Program Connects Customers w...les Collected with DNA Genotek Products , ...009 -- DNA Genotek , a leading provider of produc... and preparation, today announced its new global p...ancements for DNA Genotek,s partner community and ...
(Date:11/23/2009)...AMPAIGN, Ill. You can think of it as origami ver...ity of Illinois have developed a technique for fab...icon structures from thin films by coupling photol...pillary interactions. , The films, only a few mic...ot possible with thicker pieces of the same materi...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
.... 28 Beckman,Coulter, Inc. (NYSE: BEC ), announc...ents with Adventist Health to provide a broad rang...t approximately $36 million over,six years. Advent... care,system with facilities in California, Hawaii...scom.com/cgi-bin/prnh/20031202/BECLOGO ), Under t...
...um Drives 71% Year-Over-Year Growth in Core ... Calif., Oct. 28 Cepheid (Nasdaq:,CPHD) today rep....9,million, an increase of 24% over the third quar...$(0.11) per share, which compares to revenue of $3....09) per share, in the third,quarter of fiscal 200...
...ovavax, Inc.,(Nasdaq: NVAX ) a clinical-stage vac...vi, President and Chief Executive Officer, will be... am. (PT) on October 30, 2008 at the,Palace Hotel ...vide an,overview of the company,s strategy, resear...esentation can be accessed via the Company website...
Other Biology Technology:Beckman Coulter Signs Agreements with Adventist Health; Broad Product Offering Enhances Delivery of Quality Patient Care 2Cepheid Reports Third Quarter Revenue of $44.9 Million 2Cepheid Reports Third Quarter Revenue of $44.9 Million 3Cepheid Reports Third Quarter Revenue of $44.9 Million 4Cepheid Reports Third Quarter Revenue of $44.9 Million 5Cepheid Reports Third Quarter Revenue of $44.9 Million 6Cepheid Reports Third Quarter Revenue of $44.9 Million 7Cepheid Reports Third Quarter Revenue of $44.9 Million 8Cepheid Reports Third Quarter Revenue of $44.9 Million 9Cepheid Reports Third Quarter Revenue of $44.9 Million 10Cepheid Reports Third Quarter Revenue of $44.9 Million 11Cepheid Reports Third Quarter Revenue of $44.9 Million 12Cepheid Reports Third Quarter Revenue of $44.9 Million 13
(Date:11/24/2009)...of debate. A high-profile study a few years ago su...arbon from trees and leaves, evidence for a very c...ystems. , But new research from the University o...Algae provide a much richer diet for fish and othe...is week in the Proceedings of the National Academ...
(Date:11/23/2009)...vidence that the "synergistic" effect of early-lif...on and indoor endotoxin causes more harm to develo... , Environmental health scientists at the Univer...hown that children exposed to both high levels of ...ing early life are six times more likely to experi...
(Date:11/23/2009)...of day matters to forest trees dealing with drough... team led by Professor Malcolm Campbell, Universit...arch and colleagues in the department of cell and ...pitalizing on their previous work to decode the ge...d how poplar trees use their 45,000 genes to respo...
Breaking Biology News(10 mins):Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2Time of day matters to thirsty trees, U of T researcher discovers 2Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 1Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 2Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 1Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 2Austrian IT Solutions Provider x tention IT GmbH Implements Entrust Versatile Authentication Platform 49723 3ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 1ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 2ThromCat 28R 29 XT 28TM 29 Thrombectomy Catheter System Receives CE Mark 49718 3
...ist has discovered key appetite control cells in t...ased hunger and potentially weight-gain as we grow...oendocrinologist with Monash University,s Departme..., Dr Andrews found that appetite-suppressing cell...aid the degeneration is more significant following...
... many men during their fight against prostate canc...searchers have found. The findings were published ...edings of the National Academy of Sciences . , Th...edeviled patients for decades. Hormone therapy, a ...ncer, generally keeps the cancer at bay for a year...
...s(TM) Wireless Data Communications Link School ..., WALL, N.J., Aug. 20 BIO-key International,Inc....sed biometric,identification and wireless public s...of MobileSRO(TM) and MobileCampus(TM), silent, sec...-12 schools and higher,education, respectively., ...
Other Biology News:Killer carbs -- Monash scientist finds the key to overeating as we age 2Why a common treatment for prostate cancer ultimately fails 2Why a common treatment for prostate cancer ultimately fails 3Why a common treatment for prostate cancer ultimately fails 4BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 2BIO-key(R) Announces Emergency Alert and Management Solutions for Schools and Campuses 3
Mouse Anti-Human CD182 (CXCR2) Monoclonal Antibody, Unconjugated, Clone 5E8/CXCR2 from BioLegend
Rabbit Anti-Human Purinergic Receptor P2Y12 Polyclonal Antibody, Unconjugated from IMGENEX
Goat Anti-Human AGAP1 / Centaurin, gamma 2 Polyclonal Antibody, Unconjugated from IMGENEX
Rabbit Anti-Human CLAN Polyclonal Antibody, Unconjugated from IMGENEX
Biology Products: